Somatic mutation detection in human biomonitoring

Somatic cell gene mutation arising in vivo may be considered to be a biomarker for genotoxicity. Assays detecting mutations of the haemoglobin and glycophorin A genes in red blood cells and of the hypoxanthine-guanine phosphoribosyltransferase and human leucocyte antigenes in T-lymphocytes are avail...

Full description

Saved in:
Bibliographic Details
Published inPharmacology & toxicology Vol. 78; no. 6; p. 364
Main Authors Olsen, L S, Nielsen, L R, Nexø, B A, Wassermann, K
Format Journal Article
LanguageEnglish
Published Denmark 01.06.1996
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:Somatic cell gene mutation arising in vivo may be considered to be a biomarker for genotoxicity. Assays detecting mutations of the haemoglobin and glycophorin A genes in red blood cells and of the hypoxanthine-guanine phosphoribosyltransferase and human leucocyte antigenes in T-lymphocytes are available in humans. This MiniReview describes these assays and their application to studies of individuals exposed to genotoxic agents. Moreover, with the implementation of techniques of molecular biology mutation spectra can now be defined in addition to the quantitation of in vivo mutant frequencies. We describe current screening methods for unknown mutations, including the denaturing gradient gel electrophoresis, single strand conformation polymorphism analysis, heteroduplex analysis, chemical modification techniques and enzymatic cleavage methods. The advantage of mutation detection as a biomarker is that it integrates exposure and sensitivity in one measurement. With the analysis of mutation spectra it may thus be possible to identify the causative genotoxic agent.
ISSN:0901-9928
DOI:10.1111/j.1600-0773.1996.tb00220.x